首頁 > 市場調查報告書 > 製藥

癌症

歐洲膠質瘤治療市場預測至 2030 年 - 區域分析 - 按疾病、治療類型、等級和最終用戶

市場調查報告書

商品編碼

1452586

歐洲膠質瘤治療市場預測至 2030 年 - 區域分析 - 按疾病、治療類型、等級和最終用戶

Europe Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 96 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

歐洲神經膠質瘤治療市場預計將從2022年的9.5999億美元成長到2030年的19.051億美元。預計2022年至2030年CAGR為8.9%。

高惡性度膠質瘤盛行率的增加推動了歐洲膠質瘤治療市場

高惡性度神經膠質瘤包括侵襲性腦瘤，如膠質母細胞瘤、間變性星狀細胞瘤和少突膠質細胞瘤。這些腫瘤的特徵是快速生長、侵襲行為和對常規治療方法的抵抗。高惡性度膠質瘤是一種尚未完全了解的多方面腫瘤，這是其發生率增加的主要原因。此外，人口老化、環境暴露、遺傳傾向和診斷能力的提高是導致大量病例的其他顯著因素。膠質瘤，特別是膠質母細胞瘤，因其位於大腦內且能夠破壞關鍵神經功能而對患者的生活造成毀滅性影響而聞名。

最常見且最危險的腦腫瘤類型是膠質母細胞瘤。在全球範圍內，每年發現超過 25 萬例新發原發性惡性腦腫瘤病例，其中膠質瘤佔其中的 77%。它仍然是一種罕見疾病，佔原發性惡性腦腫瘤的 50% 以上。

歐洲神經膠質瘤治療市場概述

歐洲的歐洲神經膠質瘤治療市場分為法國、德國、義大利、西班牙、英國和歐洲其他地區。該地區在全球市場中佔有第二大佔有率，這可歸因於腦腫瘤病例數量的增加、法國腦腫瘤治療技術的進步、英國神經系統疾病盛行率的增加以及英國醫療保健投資的激增。德國。英國的醫療保健部門擁有發達的先進醫療技術和設備。根據英國國家衛生服務中心統計，英國每年有超過11,000人被診斷出患有腦腫瘤，其中近50%的腫瘤是癌性的。根據 Globocan 2020資料，英國記錄了約 7,697 例新發腦癌和中樞神經系統癌症病例。由於發病率迅速上升，一些私人和政府組織正在投資癌症研究。根據英國癌症研究中心(BCCR0001) 於2021 年4 月發布的與腦腫瘤和兒童癌症研究相關的書面證據，英國癌症研究中心自2018 年以來已承諾投入3545 萬美元，透過資助腦腫瘤研究和啟動腦腫瘤研究來鼓勵腦腫瘤研究。卓越中心和輻射研究網路。該中心在2019-2020年投資1,520萬美元用於腦腫瘤研究，並在2019-2020年投資1,112萬美元用於影響兒童和青少年的癌症研究，成為英國腦腫瘤領域最大的研究資助者之一。

歐洲膠質瘤治療市場收入及 2030 年預測（百萬美元）

歐洲神經膠質瘤治療市場細分

歐洲神經膠質瘤治療市場按疾病、治療類型、等級、最終用戶和國家細分。

根據疾病，歐洲神經膠質瘤治療市場分為星狀細胞瘤、少突星狀細胞瘤和少突膠質細胞瘤。 2022 年，星狀細胞瘤細分市場佔據歐洲神經膠質瘤治療市場的最大佔有率。

依治療類型，歐洲膠質瘤治療市場分為手術、化療、放射治療等。 2022年，手術細分市場在歐洲神經膠質瘤治療市場中佔最大佔有率。

根據級別，歐洲神經膠質瘤治療市場分為低級別和高級別。 2022 年，高層級細分市場在歐洲神經膠質瘤治療市場中佔有更大佔有率。

根據最終用戶，歐洲神經膠質瘤治療市場分為醫院和診所以及門診手術中心。 2022 年，醫院和診所細分市場在歐洲神經膠質瘤治療市場中佔有更大佔有率。

根據國家/地區，歐洲神經膠質瘤治療市場分為法國、德國、義大利、西班牙、英國和歐洲其他地區。 2022 年，德國在歐洲神經膠質瘤治療市場佔據主導地位。

Amgen Inc、Amneal Pharmaceuticals Inc、Biocon Ltd、F. Hoffmann-La Roche Ltd、Karyopharm Therapeutics Inc、Merck & Co Inc、Pfizer Inc、Sun Pharmaceutical Industries Ltd 和 Teva Pharmaceutical Industries Ltd 是在歐洲營運的一些領先公司神經膠質瘤治療市場。

High-grade gliomas include aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. These tumors are characterized by their rapid growth, infiltrative behavior, and resistance to conventional treatment methods. High-grade gliomas are multifaceted tumors that are not yet fully understood, which is a major reason for their increasing incidence. Moreover, aging populations, environmental exposure, genetic predispositions, and improved diagnostic capabilities are other notable factors that result in a large number of cases. Gliomas, particularly glioblastomas, are known for their devastating impact on patients\' lives due to their location within the brain and ability to disrupt critical neurological functions.

The most frequent and dangerous type of brain tumor is glioblastoma. Globally, more than 250,000 new cases of primary malignant brain tumors are detected each year, with gliomas accounting for 77% of these occurrences. It still remains a rare disease, accounting for over 50% of primary malignant brain tumors.

Europe Glioma Treatment Market Overview

The Europe glioma treatment market in Europe is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe. The region holds the second-largest share of the global market, which can be attributed to the increasing number of brain tumor cases, technological advancements in brain tumor treatments in France, the increasing prevalence of neurological disorders in the UK, and surging healthcare investments in Germany. The healthcare sector in the UK has access to well-developed advanced medical technologies and devices. According to the United Kingdom National Health Service, more than 11,000 people are diagnosed with brain tumors in the UK each year, of which nearly 50% of tumors are cancerous. Per the Globocan 2020 data, the UK recorded about 7,697 new cases of brain and central nervous system cancer. As a result of the burgeoning incidence, several private and government organizations are investing in cancer research. As per the written evidence related to brain tumor and childhood cancer research from Cancer Research UK (BCCR0001), released in April 2021, Cancer Research UK has committed USD 35.45 million since 2018 to encourage brain tumor research through funding calls for brain tumor research and launching centers of excellence and a radiation research network. The center invested USD15.20 million in brain tumor research, and USD 11.12 million in cancer research affecting children and adolescents in 2019-2020 to become one of the largest research funders in the field of brain tumors across the UK.

Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

Europe Glioma Treatment Market Segmentation

The Europe glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the Europe glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Europe glioma treatment market in 2022.

Based on treatment type, the Europe glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Europe glioma treatment market in 2022.

Based on grade, the Europe glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Europe glioma treatment market in 2022.

Based on end user, the Europe glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Europe glioma treatment market in 2022.

Based on country, the Europe glioma treatment market is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe. Germany dominated the Europe glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Europe glioma treatment market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Government Funding for Glioma Treatment
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector in Emerging Economies
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Glioma Treatment Market - Europe Market Analysis

5.1 Europe Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 Europe Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 Europe Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 Europe Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Europe Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Glioma Treatment Market - Country Analysis

10.1 Overview
- 10.1.1 Europe Glioma Treatment Market, by Country
  - 10.1.1.1 UK
    - 10.1.1.1.1 UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.1.2 UK: Europe Glioma Treatment Market, by Disease
    - 10.1.1.1.3 UK: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.1.4 UK: Europe Glioma Treatment Market, by Grade
    - 10.1.1.1.4.1 UK: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.1.4.2 UK: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.1.5 UK: Europe Glioma Treatment Market, by End User
  - 10.1.1.2 Germany
    - 10.1.1.2.1 Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.2.2 Germany: Europe Glioma Treatment Market, by Disease
    - 10.1.1.2.3 Germany: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.2.4 Germany: Europe Glioma Treatment Market, by Grade
    - 10.1.1.2.4.1 Germany: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.2.4.2 Germany: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.2.5 Germany: Europe Glioma Treatment Market, by End User
  - 10.1.1.3 France
    - 10.1.1.3.1 France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.3.2 France: Europe Glioma Treatment Market, by Disease
    - 10.1.1.3.3 France: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.3.4 France: Europe Glioma Treatment Market, by Grade
    - 10.1.1.3.4.1 France: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.3.4.2 France: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.3.5 France: Europe Glioma Treatment Market, by End User
  - 10.1.1.4 Italy
    - 10.1.1.4.1 Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.4.2 Italy: Europe Glioma Treatment Market, by Disease
    - 10.1.1.4.3 Italy: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.4.4 Italy: Europe Glioma Treatment Market, by Grade
    - 10.1.1.4.4.1 Italy: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.4.4.2 Italy: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.4.5 Italy: Europe Glioma Treatment Market, by End User
  - 10.1.1.5 Spain
    - 10.1.1.5.1 Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.5.2 Spain: Europe Glioma Treatment Market, by Disease
    - 10.1.1.5.3 Spain: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.5.4 Spain: Europe Glioma Treatment Market, by Grade
    - 10.1.1.5.4.1 Spain: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.5.4.2 Spain: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.5.5 Spain: Europe Glioma Treatment Market, by End User
  - 10.1.1.6 Rest of Europe
    - 10.1.1.6.1 Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.6.2 Rest of Europe: Europe Glioma Treatment Market, by Disease
    - 10.1.1.6.3 Rest of Europe: Europe Glioma Treatment Market, by Treatment Type
    - 10.1.1.6.4 Rest of Europe: Europe Glioma Treatment Market, by Grade
    - 10.1.1.6.4.1 Rest of Europe: Europe Glioma Treatment Market, by Low Grade
    - 10.1.1.6.4.2 Rest of Europe: Europe Glioma Treatment Market, by High Grade
    - 10.1.1.6.5 Rest of Europe: Europe Glioma Treatment Market, by End User

11. Europe Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Sun Pharmaceutical Industries Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Amgen Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Teva Pharmaceutical Industries Ltd
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Pfizer Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Amneal Pharmaceuticals Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Karyopharm Therapeutics Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Biocon Ltd
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Europe Glioma Treatment Market Segmentation
Table 2. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 3. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 4. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 5. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 6. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 7. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 8. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 9. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 10. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 11. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 12. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 13. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 14. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 15. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 16. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 17. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 18. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 19. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 20. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 21. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 22. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 23. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 24. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 25. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 26. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 27. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 28. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 29. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 30. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 31. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 32. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Disease
Table 33. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - Treatment Type
Table 34. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 35. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 36. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 37. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) - End User
Table 38. Organic Developments Done By Companies
Table 39. Inorganic Developments Done By Companies
Table 40. Glossary of Terms, Europe glioma treatment market

List Of Figures

Figure 1. Europe Glioma Treatment Market Segmentation, By Country
Figure 2. Europe Glioma Treatment Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Europe Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
Figure 6. Astrocytoma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Oligodendroglioma: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
Figure 10. Surgery: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Chemotherapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Radiation Therapy: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
Figure 15. Low Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Grade I: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Grade II: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. High Grade: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Grade III: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Grade IV: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
Figure 22. Hospital & Clinics: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Ambulatory Surgical Centers: Europe Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Europe Glioma Treatment Market, By Country, 2022 ($Mn)
Figure 25. Europe Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 26. UK: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. Germany: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. France: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. Italy: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Spain: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Rest of Europe: Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Growth Strategies Done by the Companies in the Market, (%)